Figure 7.

Tim-AIII suppresses tumor progression in vivo. A C57BL/6J mice that carried tumor derived from LLC cells subcutaneous xenografts tumor were administered Tim-AIII (low dose: 12.5 mg/kg or high dose: 50 mg/kg) or PBS every other day. B Representative image of the subcutaneous tumor of xenografts in different groups of C57BL/6J mice. C The tumor curves of C57BL/6J mice in different groups. D The weights of the tumor derived from LLC cells subcutaneous xenografts tumor. E Body weights of the C57BL/6J mice during the experimental period. F BALB/c-nu/nu nude mice that carried tumor derived from H1299 cells subcutaneous xenografts tumor were administered Tim-AIII (low dose: 12.5 mg/kg or high dose: 50 mg/kg) or PBS every other day. G Representative image of the subcutaneous tumor of xenografts in different groups of BALB/c-nu/nu nude mice. H The tumor curves of BALB/c-nu/nu nude mice in different groups. I C57BL/6J mice with LLC cells-derived lung metastasis tumor through the tail vein were intraperitoneal injection administered intraperitoneally Tim-AIII (Low dose: 12.5 mg/kg or high dose: 50 mg/kg) or PBS every other day. J Representative image of the lung of C57BL/6J mice in different groups. K The weights of the lung of C57BL/6J mice in different groups. L Representative flow cytometry results of Treg cells in the tumor microenvironment of LLC cells derived subcutaneous xenografts tumor microenvironment. M Quantitative analyses of Treg cells in LLC cells-derived subcutaneous xenografts. N The protein expression of HSP90 and GPX4 was examined by WB in LLC cells-derived subcutaneous xenografts tumor. Quantitative data were presented as mean ± SD. ^*p< 0.05, ^**p < 0.01, ^***p < 0.001.